Clinical trials: Prednisone, completed
Kidney Transplantation
A Study to Assess the Efficacy and Safety of ASKP1240 in de Novo Kidney Transplant Recipients
The purpose of this study is to evaluate the efficacy and safety of ASKP1240, an anti-CD40 monoclonal antibody, for the prophylaxis of organ rejection after kidney transplantation.
- Trial name
- NCT01780844
- Testing
- ASKP1240, Tacrolimus, Mycophenolate Mofetil (MMF)
- Where
- 42 sites in United States
- Volunteers
- 149 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Metastatic Castration-resistant Prostate Cancer, Metastatic Breast Cancer
A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate
The purpose of this study is to collect follow-up safety data from participants in completed abiraterone acetate studies for a maximum duration of 9 years.
- Trial name
- NCT01517802
- Testing
- Abiraterone acetate, Prednisone
- Where
- 22 sites in United States, Australia and 5 more
- Volunteers
- 32 people
- Sponsor
- Janssen Research & Development, LLC
Arthritis, Rheumatoid
The Clinical Efficacy and Safety of Iguratimod in RA and Early RA Patients for 6 Months Treatment
This study is designed to observed prospectively the efficacy and safety of 6 months treatment of iguratimod alone, or with methotrexate (MTX), hydroxychloroquine (HCQ) and prednisone step by step on Chinese rheumatoid arthritis…
- Trial name
- NCT03855007
- Testing
- Iguratimod, MTX, HCQ
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Qilu Hospital of Shandong University
Diffuse Large B-Cell Lymphoma
Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
This is a randomized, open-label, active-control, parallel-group, multicenter, multinational Phase 2 Study of the efficacy and safety of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) or Rituximab…
- Trial name
- NCT01040871
- Testing
- VELCADE, Rituximab, Cyclophosphamide
- Where
- Belgium
- Volunteers
- 164 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Hodgkin's Disease
Study of Prednisone, Vinblastine, Doxorubicin, and Gemcitabine in Elderly Patients With Advanced Stages Hodgkin's Lymphoma
The objectives of this study are to assess the feasibility and efficacy of a combination chemotherapy (PVAG) in elderly patients with advanced stages Hodgkin's lymphoma.
- Trial name
- NCT00147875
- Testing
- Prednisone, Vinblastine, Doxorubicin (Adriamycin)
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- University of Cologne
Prostate Neoplasms
An Expanded Access Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer Who Have Completed Clinical Study COU-AA-001
The purpose of this study is to provide access to abiraterone acetate for patients who have completed 12 cycles of abiraterone acetate treatment in Clinical Study COU-AA-001 and continue to receive clinical benefit from this…
- Trial name
- NCT01664728
- Testing
- Abiraterone acetate, Glucocorticoid
- Where
- United Kingdom
- Volunteers
- 54 people
- Sponsor
- Janssen Research & Development, LLC
Leukemia
Chemotherapy With or Without Imatinib and/or Peripheral Stem Cell Transplant in Acute Lymphoblastic Leukemia
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- LAL0904 (NCT00458848)
- Testing
- asparaginase, daunorubicin hydrochloride, etoposide
- Where
- 66 sites in Italy
- Volunteers
- 470 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Paraneoplastic Syndromes
Immunotherapy of the Paraneoplastic Syndromes
We treat a subset of patients with paraneoplastic neurologic disorders, including those with Yo-mediated paraneoplastic cerebellar degeneration (PCD), the Hu syndrome, which is most commonly associated with small cell lung cancer…
- Trial name
- NCT00378326
- Testing
- Tacrolimus
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Rockefeller University
Frequency of Infusion Reactions in Novel Versus Standard Protocol in Multiple Sclerosis
Observational Study of a Novel Peri Infusion Regimen on the Infusion Associated Reactions With Alemtuzumab Infusion in Patients With Multiple Sclerosis in a Canadian Clinical Setting.
To evaluate a Novel infusion protocol in MS patients treated with Alemtuzumab
- Trial name
- NCT04633967
- Testing
- Alemtuzumab Injection
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Maritime Neurology
Giant Cell Arteritis (GCA)
A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis
This study consists of two periods. The objective of Period 1 is to evaluate the efficacy of upadacitinib in combination with a 26-week corticosteroid (CS) taper regimen compared to placebo in combination with a 52-week CS taper…
- Trial name
- SELECT-GCA (NCT03725202)
- Testing
- Upadacitinib, Corticosteroid (CS)
- Where
- 172 sites in United States, Australia and 22 more
- Volunteers
- 429 people
- Sponsor
- AbbVie
Juvenile Chronic Polyarthritis, Juvenile Idiopathic Arthritis
Trial of Early Aggressive Drug Therapy in Juvenile Idiopathic Arthritis
The purpose of this study is to compare two aggressive drug regimens for children with poly-juvenile idiopathic arthritis (JIA) and extended oligo JIA.
- Conditions
- Juvenile Chronic Polyarthritis, Juvenile Idiopathic Arthritis, Juvenile Rheumatoid Arthritis
- Trial name
- NCT00443430
- Testing
- methotrexate, methotrexate - etanercept - prednisolone arm
- Where
- 15 sites in United States
- Volunteers
- 85 people
- Sponsor
- Seattle Children's Hospital
Lymphoma
S9911, Combination Chemotherapy Plus Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00003784
- Testing
- CHOP regimen, cyclophosphamide, doxorubicin hydrochloride
- Where
- 87 sites in United States
- Volunteers
- 102 people
- Sponsor
- SWOG Cancer Research Network
Idiopathic Interstitial Pneumonia
The Relationship Between Hormone Sensitivity and Imaging of Idiopathic Interstitial Pneumonia by Artificial Intelligence
Application of artificial intelligence deep learning algorithm to analyze the relationship between hormone sensitivity of idiopathic interstitial pneumonia and imaging features of high resolution CT.
- Trial name
- IIP (NCT05146934)
- Testing
- high resolution CT
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Peking University Third Hospital
ITCH
Aprepitant in the Management of Biological Therapies-related Severe Pruritus
Itch is a common side effect of anti-epidermal growth factor receptor antibodies and tyrosine kinase inhibitors. Investigators designed a pilot single-center phase II study evaluating the effects of Aprepitant, a neurokinin…
- Trial name
- AprepIt (NCT01683552)
- Testing
- Aprepitant, Prednisone, Fexofenadine
- Where
- Italy
- Volunteers
- 45 people
- Sponsor
- Campus Bio-Medico University
Autoimmune Hemolytic Disease (Cold Type) (Warm Type)
A Single-Arm Pilot Study With Low-Dose Rituximab Plus Standard Oral Prednisone In Idiopathic Autoimmune Hemolytic Anemia
The aim of this prospective study was to evaluate the activity, safety and the duration of the response of low dose rituximab associated with standard oral prednisone as first line therapy in newly diagnosed warm autoimmune…
- Trial name
- NCT01345708
- Testing
- prednisone, low dose rituximab
- Where
- 2 sites in Italy
- Volunteers
- 23 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for de Novo Ph+ ALL
The introduction of TKIs has greatly improved the prognosis of Ph+ ALL patients. The third-generation TKI ponatinib in combination with chemotherapy has demonstrated superior efficacy to first- and second-generation TKIs.
- Trial name
- NCT05594784
- Testing
- Olverembatinib, Venetoclax, prednisone
- Where
- China
- Volunteers
- 79 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Acute Lymphoblastic Leukemia, BCR-ABL1 Fusion Protein Expression
Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.
This phase II trial studies how well combination chemotherapy and dasatinib works in treating participants with Philadelphia-positive or B-cell receptor-ABL positive acute lymphoblastic leukemia.
- Conditions
- Acute Lymphoblastic Leukemia, BCR-ABL1 Fusion Protein Expression, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive
- Trial name
- NCT00390793
- Testing
- Cyclophosphamide, Cytarabine, Dasatinib
- Where
- United States
- Volunteers
- 107 people
- Sponsor
- M.D. Anderson Cancer Center
Colitis, Ulcerative
Determination of the Optimal Treatment Target in Ulcerative Colitis
Disease activity and response to therapy in ulcerative colitis (UC) can be assessed by a range of endpoints including symptoms, endoscopic mucosal activity, histological disease activity, and biomarkers.
- Trial name
- VERDICT (NCT04259138)
- Testing
- Treatment Algorithm A, Treatment Algorithm B, Treatment Algorithm C
- Where
- 58 sites in United States, Belarus and 8 more
- Volunteers
- 672 people
- Sponsor
- Alimentiv Inc.
Prostate Cancer
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
This Phase 3 study has been designed to confirm that adding custirsen to standard first-line docetaxel/prednisone treatment can slow tumor progression and enhance survival outcomes compared to standard first-line…
- Trial name
- SYNERGY (NCT01188187)
- Testing
- Custirsen, Docetaxel, Prednisone
- Where
- 140 sites in United States, Belgium and 10 more
- Volunteers
- 1,022 people
- Sponsor
- Achieve Life Sciences
Lymphoma
A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma
There are 2 parts to this study: Part 1 (dose de-escalation) and Part 2 (dose expansion). The goal of Part 1 of this clinical research study is to find the highest tolerable dose of lenalidomide in combination with obinutuzumab…
- Trial name
- NCT02529852
- Testing
- Lenalidomide, Obinutuzumab, Cyclophosphamide
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- M.D. Anderson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.